a P=0.0133; OR (95% CI): 3.09 (1.24, 7.69).
b P=0.0034; OR (95% CI): 3.23 (1.43, 7.27).
as many patients were urticaria-free
(UAS7=0) at Week 24;
30% on DUPIXENT (n=73) vs 17% on placebo
(n=75; P=0.0165; secondary endpoint)1,2,c
as many patients had well-controlled
symptoms (UAS7≤6) at Week 24;
40% on DUPIXENT (n=73) vs 23% on placebo
(n=75; P=0.0062; secondary endpoint)1,2,d
cOR (95% CI): 2.73 (1.15, 6.50).
dOR (95% CI): 3.05 (1.32, 7.02).
CI, confidence interval; CSU, chronic spontaneous urticaria; OR, odds ratio; UAS7, urticaria activity score over 7 days.
Use of DUPIXENT for the CSU indication in patients aged 2-11 years is supported by evidence from two studies of DUPIXENT in CSU patients 12+ years of age.1
Dosage and
administration
Thinking about prescribing DUPIXENT?
Find the information you need to get started.